Oncology Times - OncTimes Talk
139 episodes - English - Latest episode: 1 day ago - ★★★★ - 2 ratingsOncology Times reports essential clinical news for oncologists, hematologists and other cancer care professionals. Learn more about our award-winning journal!
Homepage Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
Meet the New Oncology Times Editorial Board Chair: Stephanie L. Graff, MD, FACP
April 12, 2023 18:52 - 15 minutes - 5.84 KBToday we are introducing the new Oncology Times Editorial Board Chair: Stephanie L. Graff, MD, FACP. In her new role, Graff will help Oncology Times continue to provide essential clinical news and analysis for the cancer care community. Graff is Director of Breast Oncology at Lifespan Cancer Institute and Assistant Professor of Medicine at Brown University. Oncology Times contributor Catlin Nalley sat down with Graff to discuss her career path and oncology care philosophy.
Ravi B. Parikh, MD, on How Machine Learning-Triggered Reminders Can Improve End-of-Life Care for Cancer Patients
March 15, 2023 18:06 - 21 minutes - 18.7 KBWhen cancer advances to an incurable stage, some patients may prioritize treatment that will extend their life as long as possible, and others may prefer a care plan that’s designed to minimize pain. Talking to patients about their prognosis and values can help clinicians develop care plans that are better aligned to each patient’s goals. However, it’s essential that the discussions happen before patients become too ill. The results of a long-term clinical trial showed electronic nudges de...
Deanna Gerber, MD, on Navigating Cervical Cancer Screening
February 22, 2023 22:00 - 13 minutes - 12.6 KBDespite increased screening and HPV vaccines, cervical cancer remains the fourth-leading cause of cancer death among women worldwide. Screening guidelines are constantly scrutinized and reassessed. The most current U.S. Preventative Services Task Force (USPSTF) guidelines recommend screening for cervical cancer every 3 years with cervical cytology alone in women aged 21 to 29 years. For women aged 30 to 65 years, the USPSTF recommends screening every 3 years with cervical cytology alone, eve...
January Research Review: Promising Results in HemOnc Clinical Trials
January 27, 2023 22:52 - 43 minutes - 38.6 KBThis episode is Research Review, a quarterly review of the research you may have missed. Today, we are covering the American Society of Hematology Annual Meeting highlights. First Up, results from the ECOG-ACRIN E1910 Randomized Phase III clinical trial showed that blinatumomab improved overall survival in newly diagnosed adult patients with b-lineage acute lymphoblastic leukemia. First author of this new research, Mark Litzow, MD, from the Mayo Clinic in Rochester, MN, talked with journali...
Unraveling a Complex Disease: Gary K. Schwartz, MD, on Sarcoma Research Highlights, Targeted Agents & Future Directions
December 22, 2022 21:14 - 30 minutes - 24.1 KBSarcoma represents an incredibly rare group of cancers comprised of 50 histologic subtypes, with approximately 13,000 new diagnoses per year. Each histologic type exhibits a unique biologic behavior, and, as such, prognosis and optimal treatment strategies vary. Sarcoma can appear anywhere in the body, and local invasion of nearby organs may make surgical resection difficult or impossible. This makes sarcoma exceedingly complex to diagnose and treat. Today on OncTimes Talk, we interview Gary...
ASH 2022: David Sallman, MD, Discusses Positive Phase I Dose Escalation Data for PRGN-3006 UltraCAR-T in AML Patients
December 20, 2022 19:56 - 17 minutes - 12.6 KBA study using chimeric antigen receptor (CAR)-T cells has proven to be safe for treating patients with relapsed or refractory acute myeloid leukemia (AML). The agent known as PRGN-3006 also brought remissions among patients who had chemotherapy for lymphodepletion prior to their CAR-T cell procedure (Abstract 4633). After the lead author of the new study, David Sallman, MD, from the Moffitt Cancer Center in Tampa, Florida, had reported the new findings at the 2022 Annual Meeting of the Ameri...
Anil K. Rustgi, MD, on the Current State of Colorectal Cancer Screening
November 23, 2022 18:47 - 24 minutes - 23.2 KBColorectal cancer is the third most diagnosed cancer and the second leading cause of cancer deaths worldwide. The current gold standard for screening, the colonoscopy, reduces cancer deaths by 67 percent, according to a 2018 study from Kaiser Permanente. So, we know screening is effective. However, obstacles remain. Colonoscopies are invasive and costs can be prohibitive. An alarming trend has also emerged, with incidence of early-onset colorectal cancer increasing over the last few decades....
Small Bytes: Phase I Study Finds Pan-AKT Inhibitor Ipatasertib Safe & Effective, Featuring Carolyn McCourt, MD
November 15, 2022 18:11 - 10 minutes - 8.3 KBBARCELONA, Spain—Patients with solid tumors expressing mutated AKT oncogenes responded to therapy with a pan-AKT inhibitor—the investigational drug ipatasertib—in a Phase I study reported at the 2022 EORTC—NCI—AACR symposium on Molecular Targets and Cancer Therapeutics. Nearly a quarter of the patients treated with the AKT blocker had their tumors shrink. These included patients with breast, endometrial, and salivary gland cancers. Tumors remained stable in just over half of the remaining p...
Small Bytes: How ctDNA Liquid Biopsies Can Detect Myeloid Malignancies & Occult Tumors
November 15, 2022 18:08 - 11 minutes - 8.6 KBBARCELONA, Spain—Liquid biopsies are increasingly used to identify cancer progression and could also provide molecular evidence of higher risk for hematologic malignancies and solid tumors, according to findings from a study of circulating tumor DNA reported at the European Organization for Research and Treatment of Cancer—National Cancer Institute—American Association for Cancer Research (EORTC-NCI-AACR) 2022 Symposium on Molecular Targets and Cancer Therapeutics. Marco Tagliamento, PhD st...
Dr. Lisa Newman on Eliminating Racial Disparities in Breast Cancer
October 28, 2022 19:44 - 25 minutes - 22.4 KBIn oncology today, there is an urgent need to better understand the implications of racial bias and disparities on the health outcomes of patients. Although breast cancer mortality rates decreased by 43 percent from 1989 to 2020, Black women remain more likely to die from breast cancer compared with White women, according to the 2022 American Cancer Society’s update on breast cancer statistics in the United States. What is the underlying cause of disparities in breast cancer? It comes down...
HemOnc Highlights: Dr. Naveen Pemmaraju on the Benefits of Tagraxofusp for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm
October 17, 2022 16:45 - 14 minutes - 10.2 KBWe talk to Naveen Pemmaraju, MD, about the results of the largest prospective BPDCN trial evaluating the CD123-targeted therapy tagraxofusp in adults with treatment-naive and relapsed/refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN). BPDCN is a rare and aggressive myeloid malignancy of the dendritic cell lineage which can affect other organs such as the lymph nodes, spleen, central nervous system, and skin. The disease carries a poor prognosis, and although it has been tr...
5 Questions on Making Cardio-Oncology More Accessible to Diverse Patient Populations with Dr. Sandeep Mittan
October 01, 2022 00:12 - 14 minutes - 1.73 KBToday on OncTimes Talk, we are getting to know a clinical researcher in 5 questions. We sat down with Sandeep Mittan, PhD, FAHA, who is a Clinical Scientist in the Division of Women’s Health and Medical Oncology at the Montefiore Medical Center and The University Hospital for Albert Einstein College of Medicine in New York. His work investigates mechanisms responsible for aging and cardiovascular pathologies. We discuss the unique characteristics of his patient population, new cardio-oncology...
ESMO 2022: For Desmoid Tumor, First Proven Therapy Shows Clear Benefit, “Should Become Standard”
September 21, 2022 23:57 - 9 minutes - 8.59 KBPARIS, France—One of the most prominent late-breaking abstracts reported at ESMO 2022 in Paris was about a rare cancer, desmoid tumor, for which no standard therapy had yet been recommended and for which there had been a clear unmet need. A team from Germany presented new findings from a randomized study using nirogacestat, a “NOTCH inhibitor”—gamma secretase inhibitor—that the investigators suggest should be adopted as standard therapy. This is pertinent to oncology practices since desmo...
ESMO 2022: PATHFINDER Presents Screening Paradigm Shift with A Blood Test to Facilitate Early Detection
September 15, 2022 19:19 - 10 minutes - 9.73 KBThe availability of a blood test for circulating DNA that can be used widely in healthy individuals to check for molecular signs of multiple cancers led Deb Schrag, MD, MPH, formerly of the Dana-Farber Cancer Center in Boston and currently Chair of the Department of Medicine at Memorial Sloan-Kettering Cancer Center, New York, to research it's use as a means of spotting a wide range of cancers early—including types for which there is currently no routine screening (Abstract 903O). At the Eu...
OncTimes Talk Research Review August 2022: Focus on Breast Cancer
August 25, 2022 14:58 - 46 minutes - 10.5 KBJournalist Peter Goodwin gives OncTimes Talk a whirlwind review of the top 2022 breast cancer research as he reports live in person from the 2022 ESMO Berlin meeting. Featuring the following interviews with leading experts: 1. Patient-Reported Outcomes Support First-Line Pembrolizumab in TNBC: David Cescon, MD, PhD, Medical Oncologist and Clinician Scientist at the Princess Margaret Cancer Centre in Toronto, Canada discusses analysis of patient-reported outcomes in the KEYNOTE-355 study in ...
Metastatic Hormone-Sensitive Prostate Cancer: Extending Life By Adding a Third Drug to Standard Regimens with Dr. Vincent Khoo
August 09, 2022 15:32 - 17 minutes - 15.8 KBIn this edition of OncTimes Talk we’re taking a look at: extending life in patients with metastatic hormone-sensitive prostate cancer by adding a third drug to standard two-drug regimens. In the randomized Phase III ARASENS trial—just published in the New England Journal of Medicine—the androgen receptor inhibitor, darolutamide, was compared with placebo when added to gold-standard two-drug therapy. Peter Goodwin visited the Royal Marsden Hospital in London UK to meet one of the ARASENS...
Liquid Biopsy ctDNA Prediction of Lung Cancer Relapse “Ready for Prime Time”
July 19, 2022 14:31 - 27 minutes - 256 KBCAMBRIDGE, UK—OncTimesTalk visits genetics pioneer Nitzan Rosenfeld PhD, group leader at the Cancer Research UK Cambridge Institute, University of Cambridge, to learn about giant steps forward for lung cancer management—reported in the Annals of Oncology—made with the sensitive assay for circulating tumor DNA (ctDNA) they developed (2022; https://doi.org/10.1016/j.annonc.2022.02.007). Rosenfeld tells reporter Peter Goodwin about the origins of his group’s genomic detection platform, and abo...
ASCO 2022 Small Bytes Episode 3: Dr. Marla Lipsyc-Sharf on Personalized ctDNA Testing in Late, HR+, HER2-Negative Breast Cancer
June 21, 2022 21:00 - 10 minutes - 4.59 KBAt the ASCO 2022 Annual Meeting, Oncology Times reporter Peter Goodwin interviewed Marla Lipsyc-Sharf, MD, Medical Oncology Fellow at Dana-Farber Cancer Institute/Mass General Brigham, who reported what she believes is the first data on ctDNA detection in late adjuvant, hormone receptor-positive breast cancer. The research showed ctDNA testing was successful in detecting measurable residual disease (MRD) prior to late clinical metastatic recurrence in women with high-risk, HR-positive, HER2-n...
ASCO 2022 Small Bytes Episode 2: Dr. Julia C. Tchou on Telehealth Weight Loss Program for Breast Cancer Survivors
June 10, 2022 14:02 - 9 minutes - 4.48 KBAt the ASCO 2022 Annual Meeting, Oncology Times reporter Peter Goodwin caught up with Julia C. Tchou, MD, PhD, FACS, from the University of Pennsylvania Health System, during her poster session. Her research examined the feasibility and acceptability of a weight loss group program via telehealth for breast cancer survivors.
ASCO 2022 Small Bytes: Dr. Alexander I. Spira on KRYSTAL-1 for Patients with Advanced/Metastatic NSCLC
June 06, 2022 20:33 - 6 minutes - 2.78 KBAt the ASCO 2022 Annual Meeting, Oncology Times reporter Peter Goodwin caught up with Alexander I. Spira, MD, PhD, FACP after his presentation on KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRASG12C mutation (Abstract 9002).
Colleague Conversations: A Look at Germline Predisposition to Hematologic Malignancies
May 23, 2022 20:11 - 18 minutes - 10 KBColleague Conversations offers insights into hematology/oncology from two different perspectives: a seasoned hematologist/oncologist and a clinician earlier in their career. Oncology Times reporter Catlin Nalley sat down with Lucy A. Godley, MD, PhD, and Gina Keiffer, MD, to discuss germline predisposition to hematologic malignancies. They delve into our growing understanding of this area, including current and future research endeavors, and examine how germline predisposition intersects wit...
Refugees & Cancer Care: Ukraine, Lebanon & Beyond Featuring Dr. Richard Sullivan & Dr. Deborah Mukherji
April 18, 2022 18:51 - 34 minutes - 31.9 KBAs Russian forces continue to bombard Ukraine, concerns are mounting about the most vulnerable citizens there, including the ill and those with cancer. Today on OncTimes Talk, we review the war in Ukraine and discuss how the war is impacting cancer patients and health systems in neighboring countries. Trying to process the refugee flow is very daunting because “the numbers are absolutely staggering,” according to Richard Sullivan, MD, PhD, a member of the World Health Organization Emergency ...
Unpacking the Role of Emotions in Mastectomy Decisions with Clara N. Lee, MD
April 04, 2022 20:40 - 22 minutes - 11.7 KBA bilateral prophylactic mastectomy for women at high risk of developing breast cancer can reduce their risk of developing the disease by up to 90 percent, according to the National Cancer Institute. An increasing number of women, including young women, are taking up this option. And while the data shows mastectomy is an effective method of reducing breast cancer risk, doctors still have to consider patients' choices which often involve other factors. For the individual patient, choosing a m...
Mitigating the Effects of Climate Change on Cancer Care With Robert A. Hiatt, MD, PhD
March 21, 2022 21:07 - 15 minutes - 12.3 KBWhile the threat of climate change may conjure images of sea level rise, extreme weather patterns, and drought, the full picture of how climate change will impact oncology practice and care is still emerging. We do know that climate change will impact cancer risk, increase exposure to carcinogens, impede access to care, and ultimately effect survival. To discuss some of these impending changes and what oncologists and patients can do to prepare, Oncology Times interviewed Robert A. Hiatt, M...
Roswell Park’s Candace S. Johnson & Congressman Brian Higgins on the Promise of Biden’s Cancer Moonshot
March 07, 2022 21:14 - 14 minutes - 12.1 KBIn early February, President Joe Biden announced that he is supercharging the Cancer Moonshot program to accelerate progress against cancer and save lives. The ambitious, jumpstarted Cancer Moonshot aims to reduce the U.S. death rate due to cancer by at least 50 percent over the next 25 years, and to improve the lives of all Americans living with and surviving cancer. The recharged Cancer Moonshot calls for a bipartisan across-the-board, all-hands-on-deck U.S. effort, which includes establi...
ASH 2021 Revisited: Plenary Sessions, ZUMA-7 & COVID Vaccines
February 21, 2022 21:30 - 41 minutes - 32.8 KBToday we revisit three studies presented at the ASH 2021 Annual Meeting. Primary Analysis of ZUMA-7 The 2021 American Society of Hematology Plenary Sessions in Atlanta, Georgia, heard data from a new study of CAR-T cell therapy in patients with diffuse large B-cell lymphoma: the Phase III randomized ZUMA-7 trial. This compared Axicabtagene Ciloleucel (Axi-Cell) with the current standard-of-care in patients whose disease had relapsed or was refractory after first-line therapy. After the t...
OncTimes Talk Research Review February 2022: Dr. Stephen Hahn, COVID, 2021 World Cancer Leaders’ Summit & Cervical Cancer News
February 07, 2022 15:35 - 1 hour - 55.1 KBToday we are bringing you a round up of three stories from around the world. We will start at the 2021 World Cancer Leader’s Summit, then move onto a story on how radiotherapy can cut late gastrointestinal toxicity for cervical cancer patients, and finish with lessons on what COVID has taught us about cancer care. All interviews are brought to you by journalist Peter Goodwin. First up, we hear from radiation oncologist Stephen Hahn, MD, who was the U.S. Food and Drug Administration's Commi...
ASH 2021 Recap: COVID-19 in Patients with Acute Leukemias & Myelodysplasia In Conversation with Dr. Pinkal Desai
December 20, 2021 23:52 - 18 minutes - 120 BytesAt the 2021 Annual Meeting of the American Society of Hematology, researchers presented more data on additional risks faced by patients who have acute leukemia or myelodysplastic syndrome and have become infected with COVID-19. In a key study presented at ASH, Dr. Pinkal Desai from New York’s Weill Cornell Medical College has identified clinical predictors of outcome among these patients. Oncology Times reporter Peter Goodwin talked with Dr. Desai about her findings and clinical recommendati...
ASH 2021 Recap: Multi Omics Sheds New Light on Malignant Transformation from Myeloproliferative Neoplasm to AML
December 15, 2021 23:05 - 17 minutes - 14 KBIn this episode, we bring you new research from the 2021 American Society of Hematology Annual Meeting about the cellular processes involving the mutated TP53 oncogene that can convert a patient’s—fairly benign—myeloproliferative neoplasm into a very threatening acute myeloid leukemia. These have been under investigation at Oxford University in the UK, using the refined genetic sequencing tool: single cell multi omics (Abstract 3). The ASH Plenary Session heard an inspiring talk on this from ...
Study Recap: After 6 Months, Pfizer COVID Vaccine Remains Effective Against Hospitalizations
November 10, 2021 22:01 - 14 minutes - 14.7 KBA new study provides support for high effectiveness of the Pfizer COVID vaccine against hospital admissions up until around 6 months after being fully vaccinated. The real-world, retrospective cohort study included data from 3.4 million Californian residents and was recently published in The Lancet. The importance of this Californian study is that up until now we've mainly relied on phase three study results to assess vaccine efficacy. This study (and another, even bigger one in Chile—with...
Research Spotlight: MET Amplification as Driver for NSCLC
September 07, 2021 20:36 - 16 minutes - 15.5 KBA new study has helped to define MET amplification as a rare but potentially actionable driver for non-small cell lung cancer (NSCLC). The paper, titled “Crizotinib in Patients With MET-Amplified NSCLC,” published in the Journal of Thoracic Oncology, introduces a third means of defining NSCLC subsets that can be targeted with a specific drug. In this episode, journalist Peter Goodwin interviews study author D. Ross Camidge, MD, PhD, Director of Thoracic Oncology at the University of Colorado ...
Colleague Conversations: Palliative Care in Oncology
September 07, 2021 20:21 - 20 minutes - 19.6 KBColleague Conversations offers insights into hematology/ oncology from two different perspectives: a seasoned hematologist/oncologist and an early-career clinician. In this installment, Oncology Times sat down with Christopher A. Jones, MD, MBA, HMDC, FAAHPM, and David Jonathan Casarett, MD, MA, FAAHPM, to discuss the relatively new field of palliative care. The discussion leads us through how the field has transformed oncology care, how palliative care physicians can address issues like raci...
OncTimes Talk Research Review May 2021
May 13, 2021 14:09 - 39 minutes - 8.9 KBWhat’s in the OncTimesTalk, May 2021 Edition? New clinical findings on: Nivolumab in gastro-esophageal cancer, CDK4/6 inhibition for breast cancer, COVID-19 vaccination limitations, sitagliptin/graft-versus-host disease, breast cancer individualization, neo-adjuvant chemotherapy for rectal cancer. Featuring: Ronan Kelly (Austin TX), Erica Mayer (Boston MA), Sibylle Loibl (Frankfurt, Germany), Shabir Madhi (Johannesburg South Africa) and Thierry Conroy (Nancy, France). I...
Straight Talk with Dr. Brian J. Bolwell: Values
November 21, 2020 21:25 - 13 minutes - 26.8 KBWelcome to the Oncology Times Podcast. Today on the Pod - Why do relatively few leaders live good values consistently? Why are so many people, especially in academic medicine, consumed with values that are emotion-based? We will discuss these ideas and more with Dr. Brian J. Bolwell, the Chairman of the Taussig Cancer Institute and Professor of Medicine at the Cleveland Clinic Lerner School of Medicine. Today Dr. Bolwell revisits his Oncology Times column on “Values” and outlines how to grow...
Straight Talk with Dr. Brian J. Bolwell: Moments
September 24, 2020 04:48 - 15 minutes - 30.2 KBIn his recurring Oncology Times column “Straight Talk: Today's Cancer Centers,” Brian J. Bolwell, MD dispenses wisdom on how to be a better leader. In this episode, Dr. Bolwell revisits his column “Moments,” and discusses how to foster vulnerability, create psychological safety on a team, and embrace joy.
Young Investigators: Liam Holt, PhD, Examines High Compression on Cells & Cancer
September 24, 2020 04:36 - 10 minutes - 17.3 KBLiam Holt, PhD, speaks in analogies when describing his work focusing on compression of cancer cells and how it affects their behavior and evolution at his lab at the Institute for Systems Genetics at NYU Grossman School of Medicine. The assistant professor in the Department Of Biochemistry and Molecular Pharmacology aims to characterize how compression of cells causes genome instability specifically in pancreatic cancer.
Straight Talk with Dr. Brian Bolwell: Letting it Go
July 17, 2020 06:13 - 12 minutes - 18.8 KBOncology Times sits down with Brian J. Bolwell, MD, the Chairman of the Taussig Cancer Institute and Professor of Medicine at the Cleveland Clinic Lerner School of Medicine. In his recurring Oncology Times column Straight Talk: Today's Cancer Centers, Dr. Bolwell dispenses wisdom on how to be a better leader. In this episode, Dr. Bolwell discusses the art of forgiveness; including how to let it go when there is conflict and breach of trust.
Talking About Leadership With Brian J. Bolwell, MD, FACP
January 28, 2019 20:31 - 15 minutes - 29.3 KBLooking for insights on leadership? Listen to Brian J. Bolwell, MD, FACP, Chairman of the Taussig Cancer Institute and Professor of Medicine at the Cleveland Clinic Lerner School of Medicine, discuss his own leadership journey and lessons learned.
A Closer Look at Ultra-Rare Cancers
November 09, 2018 23:01 - 9 minutes - 17.1 KBNaveen Pemmaraju, MD, discusses the therapeutic landscape of ultra-rare cancers as well as the importance of ongoing research in these patient populations. Additionally, he shares his own passion for this area of study and how it has shaped his career.
What I Love About Hematology/Oncology: Muzaffar H. Qazilbash, MD
October 31, 2018 15:30 - 2 minutes - 2.33 KBMuzaffar H. Qazilbash, MD, from The University of Texas MD Anderson Cancer Center, Houston, discusses what he loves about hematology/oncology, including patient interactions and lifelong learning.
What I Love About Hematology/Oncology: Pamela Crilley, DO
September 24, 2018 19:10 - 59 seconds - 954 BytesFind out what intrigued HemOnc Times Editorial Advisory Board Member Pamela Crilley, DO, Cancer Treatment Center of America, Philadelphia, about working in hematology/oncology and why she is passionate about the profession.
What I Love About Hematology/Oncology: Margaret Kasner, MD, MSCE
September 24, 2018 19:07 - 3 minutes - 3.62 KBHemOnc Times Editorial Advisory Board Member Margaret ‘Margie’ Kasner, MD, MSCE, of Sidney Kimmel Cancer Center – Jefferson Health, Philadelphia, shares her passion for the field of hematology/oncology as well as one of her most memorable patient experiences.
How Health IT is Changing Oncology
April 21, 2014 18:44 - 5 minutes - 5.07 KBAndrew Zelenetz, MD, PhD, Chief of the Lymphoma Service and Vice Chair of Medical Informatics at Memorial Sloan Kettering Cancer Center, tells OT how oncologists there are training a computer to understand and compare big data sets… Here’s why he says that work will help cancer patients at MSKCC and beyond.
Are You Providing Adequate Palliative Care?
April 21, 2014 18:18 - 3 minutes - 3.05 KBDavid E. Weissman, MD, founded the Palliative Care Center at the Medical College of Wisconsin, serves as Director of the Medical School Palliative Care Education Project, and is also Co-Director of the Center to Advance Palliative Care’s initiative to help oncs meet revised standards of care (Improving Palliative Care—Outpatients [OPAL-OP]). Listen to what he told OT are the trends in palliative care he sees in practice.
CMS Innovation
April 21, 2014 17:11 - 7 minutes - 3.3 KBAlen Voskanian, MD—Innovation Advisor to the Centers for Medicare and Medicaid Services—describes the CMS project to test new payment and service delivery models. He shared with OT the key clinical implications for oncologists and the whole cancer care team.
Are You Giving Patients What They Want?
October 26, 2013 00:12 - 4 minutes - 1.88 KBSteven Wood, PhD, Healthgrades VP, explains the health care ratings company’s survey findings that reveal what cancer patients said were the top three most important factors in their treatment experiences.
Chemotherapy Order Sets—Lessons Learned
October 26, 2013 00:00 - 4 minutes - 4.24 KBTimothy Birdsall, ND, Chief Medical Information Officer at Cancer Treatment Centers of America, tells OT what goes into making the more than 300 chemotherapy order sets there. Listen to why he says it’s not easy…
A Clinical Research Consortium for MDS
August 07, 2013 17:36 - 4 minutes - 4.27 KBMikkael A. Sekeres, MD, MS—who’s co-chairing the unique initiative to bolster research for the rare disease—explains what’s on the agenda and who’s involved. Hear what he told OT about the $16-million, five-year plan.
The Role of Patient Education in Survivorship Care
August 07, 2013 17:28 - 2 minutes - 2.68 KBPatricia A. Ganz, MD, explains why implementing standards for survivorship care is just as important as other patient education efforts on the cancer care trajectory. Hear what Ganz, coauthor of the IOM’s landmark Survivorship Report, told OT.
How CancerLinQ Will Change Patient Care
August 07, 2013 17:03 - 4 minutes - 4.22 KBGeorge W. Sledge, Jr., MD—a CancerLinQ Advisory Group member—explains how the rapid learning system will affect day-to-day oncology. Listen to what Sledge told OT Contributing Writer and “Practice Matters” blogger Lola Butcher.